2023 North America Conference on Lung Cancer (NACLC) - Posters and Abstracts-PP01.112 (Poster) Treatment Patterns and Outcomes in Second-Line Advanced NSCLC Treated After Prior Platinum Chemotherapy and Immunotherapy Combination Therapy: A Real-World Study

PP01.112 (Poster) Treatment Patterns and Outcomes in Second-Line Advanced NSCLC Treated After Prior Platinum Chemotherapy and Immunotherapy Combination Therapy: A Real-World Study

Back to course

Pdf Summary

A real-world study was conducted to examine the treatment patterns and outcomes of second-line (2L) advanced non-small cell lung cancer (NSCLC) patients who had previously received platinum chemotherapy and immunotherapy combination therapy. The study aimed to evaluate overall survival (OS), time to treatment discontinuation (TTD), and time to next treatment (TTNT) for 2L treatment, as well as explore potential variations in OS based on patient characteristics.<br /><br />The study utilized data from the Flatiron Health electronic health record database and included patients with a/mNSCLC who initiated 2L treatment with non-platinum chemotherapy between January 2019 and June 2021. Patients had previously received 1L platinum chemo-IO combination therapy. The database included structured and unstructured patient-level data from approximately 280 cancer clinics.<br /><br />The results showed variations in the selection of 2L treatments based on factors such as Eastern Cooperative Oncology Group performance status (ECOG PS), mutational status, programmed death ligand 1 (PD-L1) score, and histological classification. The median OS was similar across the three most common treatments: docetaxel ramucirumab, docetaxel monotherapy, and gemcitabine monotherapy.<br /><br />In a subgroup analysis of patients with better performance status and eligible for clinical trials, improved clinical outcomes were observed compared to the overall real-world cohort. However, limitations of the study included its retrospective design and the exclusion of patients who received pemetrexed treatment after prior chemo-IO to avoid misclassification.<br /><br />The study highlights the limited treatment options and poor prognosis for patients with a/mNSCLC in the second-line setting after prior platinum chemo-IO combination therapy. It emphasizes the need for new treatment options in this context. Moreover, patients eligible for clinical trials had better survival outcomes compared to the real-world cohort.

Asset Subtitle

Davey Daniel

Keywords

real-world study

second-line

NSCLC

platinum chemotherapy

immunotherapy combination therapy

overall survival

clinical trials

retrospective design

poor prognosis

new treatment options